{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:39:11Z","timestamp":1789706351069,"version":"4.0.1"},"reference-count":37,"publisher":"Impact Journals, LLC","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,6,6]]},"DOI":"10.18632\/oncotarget.16398","type":"journal-article","created":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T07:58:07Z","timestamp":1490083087000},"page":"37502-37510","source":"Crossref","is-referenced-by-count":9,"title":["Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma"],"prefix":"10.18632","volume":"8","author":[{"given":"Fabian Dominik","family":"Mairinger","sequence":"first","affiliation":[{"name":"Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Vollbrecht","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Division of Molecular Pathology, Charit\u00e9, Berlin, Germany"},{"name":"German Cancer Consortium (DKTK), Germany"},{"name":"German Cancer Research Center (DKFZ), Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Flom","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Christian","family":"Christoph","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Werner","family":"Schmid","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kollmeier","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Helios Klinikum Emil von Behring, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut Hans","family":"Popper","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Molecular Lung- and Pleurapathology, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mairinger","sequence":"additional","affiliation":[{"name":"Department of Pathology, Helios Klinikum Emil von Behring, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Fred","family":"Henry Walter","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"},{"name":"Ruhrlandklinik, West German Lung Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,21]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/TCRM.S1603","article-title":"Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma","volume":"4","author":"Goudar","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/thorax.58.3.198","article-title":"Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors","volume":"58","author":"Klominek","year":"2003","journal-title":"Thorax"},{"key":"3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.bjc.6600673","article-title":"Chemotherapy for malignant pleural mesothelioma: past results and recent developments","volume":"88","author":"Manegold","year":"2003","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"4","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/j.lungcan.2004.04.020","article-title":"Chemotherapy for malignant pleural mesothelioma: past results and recent developments","volume":"45","author":"Manegold","year":"2004","journal-title":"Lung Cancer"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Herndon, Green, Chahinian, Corson, Suzuki, Vogelzang. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998; 113:723\u201331.","DOI":"10.1378\/chest.113.3.723"},{"key":"6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Santoro","year":"2006","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Bruzzone","year":"2013","journal-title":"Br J Cancer"},{"key":"8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Cappuzzo","year":"2008","journal-title":"Br J Cancer"},{"key":"9","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Tunesi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10","first-page":"5621","article-title":"Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer","volume":"19","author":"Hamamoto","year":"1999","journal-title":"Anticancer Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","article-title":"ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy","volume":"19","author":"Lenz","year":"2001","journal-title":"J Clin Oncol"},{"key":"12","first-page":"4097","article-title":"Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer","volume":"5","author":"Cullen","year":"1999","journal-title":"Clin Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00001813-200201000-00009","article-title":"Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives","volume":"13","author":"Itakura","year":"2002","journal-title":"Anticancer Drugs"},{"key":"14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.lungcan.2004.01.015","article-title":"Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer","volume":"45","author":"Matsuda","year":"2004","journal-title":"Lung Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/cncr.22208","article-title":"Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase","volume":"107","author":"Scagliotti","year":"2006","journal-title":"Cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1200\/JCO.2002.07.080","article-title":"Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer","volume":"20","author":"Goldberg","year":"2002","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1200\/JCO.2003.05.044","article-title":"Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes\u2019 B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study","volume":"21","author":"Wieand","year":"2003","journal-title":"J Clin Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cllc.2013.04.013","article-title":"ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma","volume":"14","author":"Christoph","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1097\/JTO.0b013e318287c224","article-title":"Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma","volume":"8","author":"Popper","year":"2013","journal-title":"J Thorac Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6604346","article-title":"Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype","volume":"98","author":"Minamoto","year":"2008","journal-title":"Br J Cancer"},{"key":"21","doi-asserted-by":"publisher","first-page":"4276s","DOI":"10.1158\/1078-0432.CCR-040010","article-title":"Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent","volume":"10","author":"Adjei","year":"2004","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0026-895X(25)09776-7","article-title":"Thymidylate synthase as a determinant of 5-fluoro-2\u2019-deoxyuridine response in human colonic tumor cell lines","volume":"34","author":"Berger","year":"1988","journal-title":"Mol Pharmacol"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/306754","article-title":"Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug response","volume":"2010","author":"Sanguedolce","year":"2010","journal-title":"J Nucleic Acids"},{"key":"24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/JTO.0b013e318260deaa","article-title":"Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma","volume":"7","author":"Stamatis","year":"2012","journal-title":"J Thorac Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1158\/1535-7163.MCT-06-0073","article-title":"Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma","volume":"5","author":"Koropatnick","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-5002(01)00407-X","article-title":"Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung","volume":"35","author":"Wada","year":"2002","journal-title":"Lung Cancer"},{"key":"27","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Selvaggi","year":"2010","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0006-2952(03)00287-9","article-title":"Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression","volume":"66","author":"Peters","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.lungcan.2009.12.002","article-title":"The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer","volume":"69","author":"Park","year":"2010","journal-title":"Lung Cancer"},{"key":"30","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.lungcan.2011.01.024","article-title":"Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed","volume":"74","author":"Yang","year":"2011","journal-title":"Lung Cancer"},{"key":"31","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1097\/JTO.0b013e3182208ea8","article-title":"Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy","volume":"6","author":"Ahn","year":"2011","journal-title":"J Thorac Oncol"},{"key":"32","doi-asserted-by":"publisher","first-page":"20166","DOI":"10.18632\/oncotarget.7737","article-title":"Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome","volume":"7","author":"Christoph","year":"2016","journal-title":"Oncotarget"},{"key":"33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Nowak","year":"2004","journal-title":"Ann Oncol"},{"key":"34","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.prp.2013.09.007","article-title":"FFPE tissue as a feasible source for gene expression analysis--a comparison of three reference genes and one tumor marker","volume":"209","author":"Hager","year":"2013","journal-title":"Pathol Res Pract"},{"key":"35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Wittwer","year":"2009","journal-title":"Clin Chem"},{"key":"36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ymeth.2009.12.006","article-title":"Why the need for qPCR publication guidelines?--The case for MIQE","volume":"50","author":"Bustin","year":"2010","journal-title":"Methods"},{"key":"37","volume-title":"R: A language and environment for statistical computing","author":"Team","year":"2015"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:39:17Z","timestamp":1750171157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":37,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,6,6]]}},"alternative-id":["16398","28415584"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16398","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,21]]}}}